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Abstract
Bone marrow derived endothelial progenitor cells (EPCs) are early precursors of mature 
endothelial cells which replenish aging and damaged endothelial cells. The authors studied a 
diabetic swine model to determine if induction of DM adversely affects either bone marrow or 
circulating EPCs and whether a HMG-CoA reductase inhibitor (statin) improves development and 
recruitment of EPCs in the absence of cholesterol lowering. Streptozotocin was administered to 
Yorkshire pigs to induce DM. One month after induction, diabetic pigs were treated with 
atorvastatin (statin, n = 10), ezetimibe (n = 10) or untreated (n = 10) and evaluated for number of 
bone marrow and circulating EPCs and femoral artery endothelial function. There was no effect of 
either medication on cholesterol level. One month after induction of DM prior to administration of 
drugs, the number of bone marrow and circulating EPCs significantly decreased (P < 0.0001) 
compared to baseline. Three months after DM induction, the mean proportion of circulating EPCs 
significantly increased in the atorvastatin group, but not in the control or ezetimibe groups. The 
control group showed progressive reduction in percentage of flow mediated vasodilatation (no 
dilatation at 3 months) whereas the atorvastatin group and ezetimibe exhibited vasodilatation, 6% 
and 4% respectively. DM results in significant impairment of bone marrow and circulating EPCs 
as well as endothelial function. The effect is ameliorated, in part, by atorvastatin independent of its 
cholesterol lowering effect. These data suggest a model wherein accelerated atherosclerosis seen 
with DM may, in part, result from reduction in EPCs which may be ameliorated by treatment with 
a statin.
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Endothelial dysfunction heralds the development of atherosclerosis and clinical events (1). 
Patients with diabetes mellitus (DM) have marked endothelial dysfunction, accelerated 
atherosclerosis and an increased risk of cardiovascular events (2). Endothelial progenitor 
cells (EPCs) are precursors of mature endothelial cells originating from the bone marrow 
that presumably replenish aging and damaged endothelial cells that line blood vessels (3,4). 
EPCs are thought to home to sites of ischemia and participate in neovascularization and 
collateral development (5–7). The number of circulating EPCs and their migratory activity is 
reduced in patients with risk factors for ischemic cardiovascular disease and negatively 
correlated with the Framingham cardiovascular risk factor score (8). Limb ischemia and 
coronary artery bypass grafting induce a rapid, transient mobilization of EPCs from the bone 
marrow.
Recent studies suggest that statins may enhance EPC differentiation and migration to sites of 
vascular injury (9,10). Two independent laboratories published data indicating that statin 
treatment increases the circulating pool of EPCs by mobilizing them from bone marrow and 
also inhibiting EPC apoptosis (11,12). It is unknown if statins directly affect bone marrow 
and circulating EPCs in the setting of cardiac risk factors, such as DM, and whether this 
effect is independent from an effect on cholesterol level.
The diabetic state is associated with decreased number of circulating EPCs (13). Also, the 
EPCs of patients with DM are characterized by decreased proliferation capacity and 
reduction of their adhesiveness and ability to form capillary tubes in vitro (14). One study of 
diabetic mice found that at sacrifice the number of bone marrow and circulating EPCs was 
reduced, but the temporal relationship was not evaluated in this small animal model (15). 
There are no published studies evaluating simultaneously the bone marrow and circulating 
EPC number in response to the diabetic state over time and/or the response of EPCs to statin 
treatment.
We previously identified a population of progenitor cells in the porcine bone marrow, called 
side population cells (SP), which differentiate into endothelial cells (16). Other studies have 
shown that SP cells are not only present in bone marrow, but they are also observed in the 
arterial wall where they participate in angiogenesis (17).
In this study, we tested the hypothesis that the diabetic state will reduce EPCs in the bone 
marrow as well as mobilization of EPCs. Also, we hypothesized that statins promote EPC 
mobilization from the bone marrow and increase circulating EPCs in the blood in the 
diabetic state. Although statins have been shown to mobilize EPCs and improve endothelial 
function (18). It is unknown if other classes of lipid lowering agents such as ezetimibe have 
similar effects. Accordingly, we conducted a study in a porcine model of DM evaluating the 
effects of atorvastatin and ezetimibe on bone marrow and circulating EPC number and 
endothelial function to determine if statins and/or ezetimibe promote mobilization of EPCs 
and/or improve endothelial function in the setting of DM.
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Methods
Study Design
A total of 30 pigs were studied at baseline and 1 month after induction of DM for bone 
marrow and circulating EPCs, endothelial function and a marker of inflammation, 
lipoprotein phospholipase A2 (Lp-PLA2). This study was performed following approval of 
the Institutional Animal Care and Use Committee of the University of Pennsylvania. One 
month after induction of DM, pigs were randomly assigned to receive atorvastatin 10 mg per 
day or ezetimibe 10 mg per day or were untreated for a total of 3 months. The 
aforementioned outcome measures were then repeated at study completion which occurred 
at 4 months after induction of DM.
Pig Model
Type I DM was induced in 30 Yorkshire pigs (28–30 kg) by infusing a single dose of 
streptozotocin (Sicor Pharmaceuticals, Irvine, CA, 125 mg/kg) IV over a period of 30 min 
by a Harvard pump as described in our previous publication (19). All of the pigs, including 
the controls, were made diabetic using the same protocol. Animals were recovered from 
anesthesia and returned to cages, followed by feeding that included dextrose powder to 
avoid hypoglycemic shock due to the excessive blood insulin levels after the lysis of the beta 
cells. The first blood glucose levels were measured 4 h after induction, followed by daily 
measurements, using a glucometer (Beyer, Tarrytown, NY) every day before feeding for the 
first 7 days and then on a weekly basis thereafter.
Bone Marrow Harvest
A sternal bone marrow aspirate (5 ml) was collected at baseline, prior to induction of 
diabetes, and at 1 month, 4 months after the induction of diabetes in order to assess bone 
marrow populations of EPCs. The bone marrow aspirate was collected under standard sterile 
technique while the animal was sedated as per prior published methods (16).
Side Population Cells
Porcine endothelial progenitors were identified using a modification of the procedure 
described by Goodell et al. (20,21). A functional assay using Hoechst 33342 was used to 
identify these progenitors (Fig. 1). In several species, it has been noted that stem cells efflux 
this dye resulting in a low staining population termed the side population (SP) (22,23). 
Briefly, red blood cells in porcine bone marrow or peripheral blood were removed using 1× 
ammonium chloride solution and a single-cell suspension was achieved. Cells were 
aliquoted (2 × 106 cells per tube) and incubated for 2 h at 37°C with Hoechst 33342 (Sigma-
Aldrich) at a concentration of 5 μg/ml. with or without 50 μM verapamil (Sigma-Aldrich). 
Following two washes with ice cold HBSS + serum, surface staining for CD45 was 
performed using an indirect method (mouse antiporcine CD45/FITC goat anti-mouse Ig) to 
identify hematopoietic progenitors. Just prior to analysis, propidium iodide (Molecular 
Probes, 2 μg/ml) was added as a viability marker. All analyses were performed on a BD 
LSRII digital high speed analytical flow cytometer (BD Biosciences). After UV excitation at 
355 nm, Hoechst blue (collected through a 405/30 filter) and red (670/40 filter) signals were 
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analyzed to detect the SP. One hundred thousand live cells were collected per file and EPCs 
were defined as propidium iodide negative, singlets (based on light scatter), dim CD45 and 
positive for SP. Data were analyzed using FlowJo (TreeStar, Inc.) software.
Endothelial Function
In vivo endothelial function was determined at baseline, as well as 1 month and 4 months 
after DM induction. The 1-month measurement was done prior to randomization. Flow-
mediated dilatation (FMD), the measurement of endothelial function, was evaluated by 
quantifying changes in femoral artery diameter following a 5-min femoral arterial occlusion 
with a mechanical clamp. The femoral artery was imaged in the longitudinal plane using an 
ultrasound system equipped with vascular software for two-dimensional imaging, color and 
power Doppler, an internal ECG, and a linear array transducer with a minimum frequency of 
7 MHz. Shear stress-induced vasodilatation was measured utilizing longitudinal images 
acquired 1 min after release of occlusive pressure. Analysis of luminal diameter was 
measured using digital still images captured during end-diastole using specialized imaging 
software (Medical Imaging Applications, Brachial Analyzer Iowa City, Iowa). The lumen 
intima was identified automatically by edge detection software, with manual adjustments 
performed when necessary. Arterial diameters (mm) were calculated as the mean distance 
between the anterior and posterior wall at the vessel–blood interface. Flow-mediated 
vasodilatation was expressed as the ratio of diameter change to baseline diameter.
Measurement of Lp-PLA2 Mass and Activity
Measurement of Lp-PLA2 mass was done with the diaDexus “PLAC” immunoassay using 
two specific monoclonal antibodies described by Caslake et al. (24). The assay system 
utilizes monoclonal anti-Lp-PLA2 antibody (2C10) directed against Lp-PLA2 for solid phase 
immobilization on the microwell strips. Plasma samples were added to the plate and 
incubated for 10 min at 20–26°C. A second monoclonal anti-Lp-PLA2 antibody (4B4) 
labeled with the enzyme horseradish peroxidase (HRP) was then added and reacted with the 
immobilized antigen at 20–26°C for 180 min, resulting in the Lp-PLA2 molecules being 
captured between the solid phase and the enzyme-labeled antibodies. The wells are washed 
with a supplied buffer to remove any unbound antigen. The substrate, tetramethylbenzidine 
(TMB), is then added and incubated at 20–26°C for 20 min, resulting in the development of 
a blue color. Color development is stopped with the addition of Stop Solution, changing the 
color to yellow. The absorbance of the enzymatic turnover of the substrate is determined 
spectrophotometrically at 450 nm and is directly proportional to the concentration of Lp-
PLA2 present. A set of Lp-PLA2 Calibrators is used to plot a standard curve of absorbance 
versus Lp-PLA2 concentration from which the Lp-PLA2 concentration in the test sample can 
be determined.
The plasma Lp-PLA2 activity was measured with a colorimetric activity method (CAM) 
provided by diaDexus, Inc. (South San Francisco, CA, USA). Samples, standards, or 
controls are added to wells of a non-binding 96-well microplate, followed by addition of 
CAM reaction buffer containing substrate. In the presence of Lp-PLA2 enzyme, the 
substrate is converted upon hydrolysis by the phospholipase enzyme. The change in 
absorbance is immediately measured at 405 nm over 60–180 s. The level of Lp-PLA2 
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activity in nmol/min/mL is calculated from the slope (OD405/min), based on a standard 
conversion factor from a p-nitrophenol calibration curve.
Statistical Analysis
For each treatment group, changes in glucose, cholesterol and weight over time were 
analyzed using paired t-tests. The FMD data were analyzed using a mixed effects model 
where correlations between repeated measurements were considered on the same animals 
across time (25). Terms in the model included age of animal, treatment group (control, 
atorvastatin, ezetimibe), side (left versus right artery) and time of measurement (1 min or 2 
min) after initiation of hyperemia. Differences in the effect of treatment over time were 
examined using an interaction between treatment group and age of animal using a global F-
test to test for differences in the effects of animal age among the different treatment groups, 
followed by Wald tests to examine specific changes (e.g., baseline versus 1 month).
For EPC experiments, linear regressions were constructed using the individual paired data 
time points (baseline versus 1 month and 1 versus 4 months. For the analysis of 1 month 
versus 4 months, the baseline percentage of EPCs was added to the model in an analysis of 
covariance to account for variability among animals. Linear regression analysis was used to 
examine the association between the mean FMD change and EPC change between baseline 
and 1 month. For this analysis, mean FMD was determined across both sides and times of 
measurement for each animal.
For analysis of Lp-PLA2, differences between time points were examined using paired 
Wilcoxon signed-rank tests using only those animals with measurements at both time points 
of interest. To ensure maximum power to detect effects, all of the treatment groups were 
pooled for the comparison of animals from baseline to 1 month. For the comparison of 
animals from 1 month to post-treatment, treatment groups were analyzed separately (26).
Data were analyzed using R 2.6; a Type I error of 0.05 was used to declare significance for 
hypothesis tests and any P value (P) less than 0.10 was reported. All hypothesis tests were 
two-sided except those for the comparison of EPC at baseline versus 1 month, and for 4 
months versus 1 month. Here a priori hypotheses indicated that we should test only for a 
decrease in EPCs between baseline and 1 month and an increase between 1 month and 4 
months. No corrections for multiple comparisons were performed.
The statistical methods were chosen with the goal of balancing the competing need to 
maximize power and protect against false positives/invalid type I error rates in our 
hypothesis tests. The experiment was initially designed to look at within animal differences, 
and with the available sample sizes we anticipated that we would have insufficient statistical 
power to make meaningful comparisons between groups. Thus rather than carry out an 
ANOVA-type analysis comparing time, treatment and treatment by time effects, we focused 
our analyses on a limited number of within-subject analyses, specifically comparing the 
combined baseline versus 1 month and treatment-specific 1 month versus 4 month time 
points. This analysis suggested that EPCs significantly increased in the atorvastatin group, 
but the P value did not initially achieve strict statistical significance. We adjusted 
statistically for baseline variability in EPCs in the analysis using an analysis of covariance. 
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Our study may have been limited somewhat by statistical power; however, the findings are 
unique and we have reported both P values and estimates of the effect, with the hope of 
stimulating further research and hypotheses in this area.
Results
Laboratory Data
The animal weight and laboratory data is listed in Table 1. There were three noteworthy 
changes over time in these data. The mean glucose level was significantly elevated above 
baseline in all three groups 1 month after induction of diabetes (P < 0.0001). When analyzed 
separately by group, changes in cholesterol levels declined from baseline to 1 month but not 
significantly. Since the animals were not yet randomized to treatment at 1 month, we also 
used a more powerful analysis, comparing cholesterol levels at 1 month versus baseline in a 
pooled comparison of all animals. Here the reduction in cholesterol was statistically 
significant (P = 0.005). Lastly, the animals from all three groups gained weight in the final 4 
weeks of the study compared to week 1 of the study (P < 0.05 for each group).
Bone Marrow and Circulating EPCs
The number of bone marrow EPCs was measured at baseline, 1 month and 4 months after 
induction of DM, based on identification of SP (Fig. 1). One month following the induction 
of DM, the mean levels of both bone marrow-derived and circulating EPCs were 44.7% (P = 
0.001) and 26.9% (P < 0.0001) respectively below baseline (Fig. 2). In the atorvastatin 
group at 4 months, the mean levels of bone marrow-derived and circulating EPC's increased 
181% (P = 0.065) and 203% (P = 0.080) above the level observed at 1 month. While 
statistical significance was not achieved for this direct comparison, the result for circulating 
cells (P = 0.043), but not marrow-derived cells (P = 0.065) achieved significance after 
adjusting for variation in baseline levels of EPCs. In the ezetimibe group at 4 months, the 
mean levels of bone marrow-derived and circulating EPC's were 76% and 94%, 
respectively, of the levels observed at 1 month (P > 0.05, NS). In the control group at 4 
months, the mean levels of bone marrow-derived and circulating EPC's were 63% and 68%, 
respectively, of the levels observed at 1 month (P > 0.05, NS). Taken together, these data 
demonstrate that treatment of diabetic pigs with atorvastatin, but not ezetimibe, significantly 
increased circulating EPCs.
Endothelial Function
Next, we examined the effect of treatment on endothelial function. Prior to induction of DM, 
femoral arteries demonstrated a flow-mediated vasodilatory response of 11.7%; comparable 
in magnitude to that reported in humans (8). The mean FMD did not differ significantly 
among the right or left femoral artery or at 1 min or 2 min post-hyperemia. One month after 
induction, the mean FMD decreased significantly (P < 0.0001, Fig. 3) demonstrating the 
effect of diabetes. There was also strong evidence of differences in FMD over time that 
varied among the control and treated groups (P < 0.0001, Fig. 3). At 4 months, the mean 
FMD was lower than the 1-month (P = 0.027) for control group, however, in contrast, the 
atorvastatin group mean FMD was significantly higher (P = 0.003, Table 2). In the 
ezetimibe treatment group at 4 months, the FMD was significantly lower than baseline (P = 
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0.007, results not shown) and also significantly lower than 1 month (P < 0.0001, Fig. 3). 
However, the mean FMD for the ezetimibe group was higher than the control group at 4 
months (P = 0.004, Table 2).
When the number of EPCs were compared to the change in FMD between baseline and 4 
weeks, animals with higher circulating EPCs at baseline had less reduction in FMD (P = 
0.027, Fig. 4). However the difference between FMD at 4 weeks and baseline was 
significantly positively associated with baseline EPCs. Thus, animals with higher baseline 
EPC's experienced less of a decrease in FMD, and in some cases actually increased FMD at 
4 weeks versus baseline (Fig. 4). No significant trends were observed between FMD 
changes and EPC levels in the marrow or when the 1-month and 4-month time points were 
compared.
Lp-PLA2
In order to characterize the state of oxidative stress Lp-PLA2, a marker of inflammation 
(27), was measured at various time points (Table 3). In association with induction of 
diabetes Lp-PLA2 activity was significantly higher compared to baseline for the three 
groups combined (P = 0.003). A strong trend in reduction of Lp-PLA2 activity was observed 
in both the atorvastatin (P = 0.055) and ezetimibe (P = 0.063) treatment groups at 4 months 
compared to baseline. The Lp-PLA2 mass was also evaluated at pre-determined time points. 
There was a trend in elevation of mass at 1 month when all groups were pooled. There was 
no significant change in Lp-PLA2 mass at the 1 month or 4 month time points compared to 
control (Table 4).
Discussion
Evaluation of endothelial progenitor numbers and function are important in many pathologic 
conditions. As with many studies of progenitors, flow cytometry offers a useful approach to 
detect these rare cells. This is the first prospective study, using a large animal model, 
showing that DM reduces both the concentration of bone marrow as well as circulating 
EPCs. Flow cytometric measurement of EPCs, using the SP approach revealed that in 
diabetic animals, administration of atorvastatin enhanced EPC mobilization to the 
circulation. Interestingly, ezetimibe did not induce a significant increase in bone marrow or 
circulating EPCs strongly suggesting that the mobilization of EPCs following treatment with 
atorvastatin is not wholly related to its cholesterol lowering effects. This effect was observed 
in pigs and may not be seen with other animals or humans.
One major difficulty in studying the effect of endothelial progenitors is that the definition in 
both humans and animals is controversial. Unfortunately the cell surface markers available 
in pigs are significantly limited compared to humans and mice. For example, there is no 
available CD34 pig surface maker for flow cytometry. Therefore, we chose to evaluate a 
progenitor population of cells in the bone marrow that has been well defined SP cells. This 
cell population was reported by Goodell et al. almost a decade ago (20,22,23). In a previous 
publication we have reported that SP cells differentiate into endothelial cells (16). In 
humans, by flow cytometry endothelial progenitors lie in the CD45 dim to negative 
population (as compared to the CD45 bright for hematopoietic progenitors) so we chose to 
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further limit our study to this population. As such, the SP population provides for study of 
EPC phenotype cells (and potentially other progenitor cells) that may be affected by diabetes 
and play a role in the phenotypic manifestations of diabetes.
As anticipated, the induction of DM was accompanied by endothelial dysfunction and 
evidence of inflammation as measured by Lp-PLA2. Treatment with either atorvastatin or 
ezetimibe improved endothelial dysfunction over time and attenuated the increase in 
inflammation. These data suggest that the potential benefits of statins and ezetimibe in the 
setting of diabetes are not solely dependent upon mobilization of EPCs from the bone 
marrow.
The clinical data examining the mechanism(s) of action of ezetimibe compared with statin 
drugs are poorly defined at present. One study of 20 patients with chronic heart failure 
showed FMD improved after simvastatin, but not ezetimibe (18). Another study that 
included 20 patients with rheumatoid arthritis revealed that both of these classes of drugs 
improved FMD (28). The results from our study indicate that in this large animal model of 
DM, statin treatment as well as ezetimibe improved endothelial function in the setting of 
normal cholesterol levels. However, the absolute value for atorvastatin group was higher at 4 
months compared to ezetimibe group.
Diabetic vasculopathy is characterized by early endothelial dysfunction and a subsequent 
marked increased risk of morbidity and mortality (2,29). A prospective study of patients 
with type II DM revealed that statin administration is efficacious in reducing the risk of first 
cardiovascular disease events, including stroke (30). Previous studies indicate that patients 
with DM have reduced levels of circulating EPCs (31,32) as well as abnormal function (33). 
Rivard et al. evaluated the effect of diabetes on angiogenesis and found that diabetes impairs 
endogenous neovascularization of ischemic tissues resulting from reduced expression of 
vascular endothelial growth factor (VEGF) (34). Prior to the current study a cause-effect 
relationship between EPCs and a biologic response, or therapeutic effect, on endothelial 
function was not discerned. Our results indicate that reduced circulating EPCs in the diabetic 
state are due to decreased bone marrow production of cells as well as decreased EPCs in the 
peripheral circulation. The potential mechanisms for increased circulating EPCs in response 
to atorvastatin are increased mobilization from marrow, increased survival (known effect in 
vitro), and reduced homing due to reduced endothelial damage. As such, the results indicate 
that the systemic effects of DM extend to the bone marrow microenvironment resulting in 
endothelial dysfunction. Furthermore, the role of DM in causing vasculopathy may be 
caused, at least in part, by endothelial injury coupled with a reduced endothelial response 
mechanism(s).
Statin drugs are reported to have pleiotropic effects beyond cholesterol lowering (35,36). 
The treatment of dyslipidemia with a statin increases the circulating pool of EPCs and 
inhibits EPC apoptosis in vitro (11,12). Clinically stable angina pectoris patients treated for 
4 weeks with atorvastatin demonstrated an increase in the number of circulating EPCs and 
increased migratory capacity ex vivo (37). However, these studies were in the setting of 
elevated cholesterol and it was not clear if the reduction in low density lipoprotein (LDL) or 
a non-cholesterol related effect was responsible for the beneficial effect on EPC 
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mobilization. The present results indicate that DM reduces both bone marrow reserves and 
circulating EPCs with accompanying endothelial dysfunction, and this effect is partially 
reversed by statin administration in the setting of normal cholesterol.
A consequence of DM is increased oxidative stress and inflammation (2). A previous 
investigation showed that DM increases oxidative stress and inflammation in coronary 
arteries of normocholesterolemic pigs (38) and the elevated Lp-PLA2 activity noted in this 
study confirms this finding. The EPC is thought to reside in the marrow and release into the 
circulation due to increased nitric oxide (NO) levels (39). The high oxidative state of DM 
likely results in uncoupling endothelial derived nitric oxide synthase (eNOS) and 
development of reactive oxygen species that impair NO availability that is important for 
EPC mobilization (4). It is likely that the reduction of circulating EPCs secondary to DM 
and the impaired endothelial dependent vasodilatation observed in this study are related to 
reduced NO availability. Statin administration has been shown to enhance EPC 
differentiation via PI 3-kinase/akt pathway (12) and this may be one pleiotropic effect that 
improves the bone marrow EPC niche and ultimately reduction in cardiovascular events in 
the diabetic population. Furthermore, HMG-CoA reductase inhibition normalizes 
endothelial function and reduces oxidative stress in the diabetic state by inhibiting activation 
of NADPH oxidase and by preventing eNOS uncoupling (40).
In conclusion, DM results in reduced levels of both bone marrow and circulating EPCs and 
was accompanied by impaired endothelial function. These detrimental effects are partially 
ameliorated by statin administration and as such demonstrate beneficial cholesterol-
independent effects of statins on EPCs and endothelial function in the setting of DM. The 
pathological mechanism(s) resulting in reduced bone marrow EPCs deserves further 
investigation.
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Figure 1. 
Detection of SP cells in porcine bone marrow. Porcine bone marrow cells were stained with 
5 μM of Hoechst 33342 for 120 min at 37°C with or without 50 μM verapamil. SP cells 
analysis was performed on BD Bioscience LSRΠ with UV laser. Gating was based on live 
(negative for PI), singlet (based on light scatter) and CD45 negative cells (A). Side 
population cells (EPCs) were clearly detected after Hoechst 33342 staining, and gated side 
population cells (EPCs) account for 0.51% of the CD45 negative cells (B). In the presence 
of verapamil, gated side population cells almost completely disappeared (C).
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Figure 2. 
Mean EPC levels across time in blood and marrow. Vertical lines indicate standard errors 
for the combined groups at baseline and 1 month, and for control: rectangles, atorvastatin 
closed circles, ezetimibe open circles at 4 months.
Mohler et al. Page 14
Cytometry A. Author manuscript; available in PMC 2014 November 05.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3. 
Mean percent flow mediated vasodilatation (FMD) time points during the study. Vertical 
lines indicate standard errors. Control: Rectangles, Atorvastatin closed circles, Ezetimibe 
open circles.
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Figure 4. 
Association between baseline EPC and FMD at baseline, 4 weeks or the difference in FMD 
between 4 weeks and baseline.
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Table 1
Mean (SEM) glucose, cholesterol and weight over timea
DM ONLY DM + ATORVASTATIN DM + EZETIMIBE
Glucose (mg/dL)
 0 month 100.0 (7.2) 115.9 (5.5) 81.6 (11.4)
 1 months 323.9 (21.3) 319.3 (24.8) 359.8 (21.8)
 4 months 307.3 (54.0) 339.4 (25.3) 306.6 (59.0)
P value
 0 vs. 1 month <0.0001 <0.0001 <0.0001
P value
 1 vs. 4 month NS NS NS
Cholesterol (mg/dL)
 0 month 110.7 (11.5) 85.9 (5.2) 89.3 (4.7)
 1 months 74.6 (6.7) 72.4 (3.9) 66.5 (5.4)
 4 months 86.4 (3.2) 78.6 (4.6) 60.5 (4.7)
P value
 0 vs. 1 month NS NS 0.06
P value
 1 vs. 4 month NS NS NS
Weight (kg)
 0 month 35.2 (2.3) 34.3 (3.3) 34.2 (3.7)
 1 months 36.1 (3.2) 33.0 (3.5) 31.9 (2.8)
 4 months 56.1 (7.6) 49.1 (3.6) 42.7 (4.8)
P value
 0 vs. 1 month NS NS NS
P value
 1 vs. 4 months 0.004 0.001 0.017
aNS indicates a P value greater than 0.10.
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Table 2
Mean (SEM) for percent FMD for atorvastatin and ezetimibe groups compared to control 
at same time pointa
AGE ATORVASTATIN EZETIMIBE
Baseline 12.96 (1.99) 9.64 (2.47)
1 month 4.45 (2.11) 12.44 (2.47)*
4 months 6.98 (2.23)* 3.96 (2.55)*
aAsterisks (*) indicate P < 0.05. Data are compared to control at same time point.
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Table 3
Lp-PLA2 activity (nmol/min/mL) for animals with paired measurements at each set of 
time pointsa
BASELINE 1 MONTH 4 MONTHS P VALUE
Control 112.7 (104, 121) 126.9 (123, 149) 131.6 (94, 169) 0.689
Atorvastatin 117.2 (109, 120) 157.5 (143, 167) 137.5 (128, 150) 0.055
Ezetimibe 112.2 (109, 128) 149.9 (134, 154) 93.5 (73, 138) 0.063
a
Entries show median (inter-quartile range). P = 0.0003 for 1 month compared to baseline when pooled among all groups.
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Table 4
Lp-PLA2 mass (mcg/L) for animals with paired measurements at each set of time pointsa
BASELINE 1 MONTH 4 MONTHS P VALUE
Control 1.1 (0.9, 1.3) 1.7 (1.3, 2.3) 1.4 (1.1, 2.1) 0.25
Atorvastatin 1.3 (0.8, 1.5) 1.2 (1.1, 1.3) 1.0 (1.0, 2.1) 1.00
Ezetimibe 1.0 (1.0, 2.0) 1.6 (1.0, 2.1) 2.1 (1.7, 2.5) 1.00
a
Entries show median (inter-quartile range). P = 0.079 for 1 month compared to baseline when pooled among all groups.
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